Manhattan BioSolutions
Manhattan BioSolutions is a biotechnology company focused on discovering and developing immunotherapies targeting innate immunity for cancer and inflammatory diseases. They leverage platforms such as microbial-based genetically engineered immune stimulators and monoclonal antibodies against innate immune sensors. The company collaborates with leading academic institutions and has received grants from NIH, NSF, and other organizations. Their mission is to develop next-generation biologic therapies to treat advanced cancers and age-related diseases.
Industries
Nr. of Employees
small (1-50)
Manhattan BioSolutions
JLabs JNJ 101 6th Avenue, 3rd Floor, New York, NY 10013
Products
RNA‑degrading protein therapeutic (lead candidate)
Engineered nuclease‑derived therapeutic (pan‑RNA degrader) developed to selectively degrade RNA in tumors and tumor microenvironment; reported favorable tolerability and prior Phase I dose‑escalation evaluation.
Synthetic Microbial Immune Stimulator (sMIST) platform
Platform of genetically modified non‑pathogenic mycobacteria engineered to induce innate and tumor‑specific adaptive immune responses; demonstrated tumor regressions in preclinical bladder cancer models.
Antibody‑drug conjugate (ADC) development programs with tumor‑cleavable linker‑payloads
Preclinical ADC programs combining proprietary antibodies with protease‑cleavable linker‑payload chemistries and next‑generation warheads for oncology applications, including pediatric indications.
RNA‑degrading protein therapeutic (lead candidate)
Engineered nuclease‑derived therapeutic (pan‑RNA degrader) developed to selectively degrade RNA in tumors and tumor microenvironment; reported favorable tolerability and prior Phase I dose‑escalation evaluation.
Synthetic Microbial Immune Stimulator (sMIST) platform
Platform of genetically modified non‑pathogenic mycobacteria engineered to induce innate and tumor‑specific adaptive immune responses; demonstrated tumor regressions in preclinical bladder cancer models.
Antibody‑drug conjugate (ADC) development programs with tumor‑cleavable linker‑payloads
Preclinical ADC programs combining proprietary antibodies with protease‑cleavable linker‑payload chemistries and next‑generation warheads for oncology applications, including pediatric indications.
Services
Research collaborations and commercial evaluation/license option agreements with academic institutions and government research centers to co‑develop monoclonal antibodies and ADC combinations.
Design and execution of in vivo efficacy studies, survival analyses, and translational pharmacology (PK/PD) to validate therapeutic candidates prior to IND filing.
Integration of computational antibody design outputs into experimental discovery workflows to accelerate generation and optimization of fully human antibody candidates.
Research and preclinical development of recombinant BCG‑based vaccine and therapeutic constructs for infectious disease prevention and cancer immunotherapy.
Research collaborations and commercial evaluation/license option agreements with academic institutions and government research centers to co‑develop monoclonal antibodies and ADC combinations.
Design and execution of in vivo efficacy studies, survival analyses, and translational pharmacology (PK/PD) to validate therapeutic candidates prior to IND filing.
Integration of computational antibody design outputs into experimental discovery workflows to accelerate generation and optimization of fully human antibody candidates.
Research and preclinical development of recombinant BCG‑based vaccine and therapeutic constructs for infectious disease prevention and cancer immunotherapy.
Expertise Areas
- Antibody‑drug conjugate (ADC) development
- Monoclonal antibody discovery and preclinical development
- Synthetic microbial therapeutics and live bacterial platforms
- RNA‑degrader protein therapeutics
Key Technologies
- Antibody‑drug conjugates (ADCs)
- Tumor‑cleavable linker chemistry
- Linker‑payload design for immune stimulation
- Topoisomerase I inhibitor warheads (preclinical payloads)